Parallax Volatility Advisers’s Tvardi Therapeutics TVRD Stock Holding History

Parallax Volatility Advisers’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14	Closed	-$8K	–	3545
2021 Q3	$8K	Hold	14	–	–	﹤0.01%	2824
2021 Q2	$7K	Buy	+14	New	+$8.87K	﹤0.01%	2793
2019 Q2	–	Sell	-1,111	Closed	-$785K	–	3934
2019 Q1	$785K	Buy	+1,111	New	+$665K	﹤0.01%	1370
2018 Q3	–	Sell	-1,528	Closed	-$1.05M	–	3777
2018 Q2	$1.05M	Buy	+1,528	New	+$777K	﹤0.01%	1080
2017 Q2	–	Sell	-556	Closed	-$368K	–	4264
2017 Q1	$368K	Buy	+556	New	+$297K	﹤0.01%	1649

Other funds holding TVRD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Parallax Volatility Advisers's TVRD Position: Q4 2021 in Review

Parallax Volatility Advisers sold out of Tvardi Therapeutics (TVRD) in Q4 2021, closing a stake of 6 shares — an estimated $3K sold.

Parallax Volatility Advisers first reported a position in TVRD in Q2 2017 and held it in 6 quarters. The position peaked at $2.39M in Q1 2019. 181 funds tracked by Wall St. Rank hold TVRD as of Q4 2021.

Parallax Volatility Advisers reported no remaining Tvardi Therapeutics position as of Q4 2021 after selling out during the quarter.
Parallax Volatility Advisers sold 6 Tvardi Therapeutics shares in Q4 2021, an estimated $3K.
Parallax Volatility Advisers first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 6 quarters.
Parallax Volatility Advisers's Tvardi Therapeutics position peaked at $2.39M in Q1 2019.
181 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2021.

Based on Parallax Volatility Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.